PMID- 17427005
OWN - NLM
STAT- MEDLINE
DCOM- 20070809
LR  - 20211216
IS  - 0043-5341 (Print)
IS  - 0043-5341 (Linking)
VI  - 157
IP  - 5-6
DP  - 2007
TI  - [Examples for vaccines against diarrheal diseases--rotavirus and traveller's 
      diarrhea].
PG  - 102-6
AB  - Diarrheal diseases constitute one of the most important health problems 
      worldwide. Children less than 5 years, living in developing countries, are 
      particularly in danger with respect to the incidence and severity of the 
      gastrointestinal disorders. Travelers to developing countries are also at risk to 
      develop diarrheal disorders; around 30-50% of them acquire so called "travelers's 
      diarrhea" caused by bacteria, viruses or protozoa. It has been estimated that 
      approximately 30-70% of diarrhea are due to bacteria, of which the most 
      frequently detected enteric pathogens are non-invasive, enterotoxigenic 
      Escherichia coli (ETEC). Their exotoxins, the heat stabile (ST) and the heat 
      labile (LT) toxins are in large part responsible for the pathogenicity of the 
      bacteria. About 20% of cases of traveler's diarrhea are caused by LT producing 
      ETEC. This heat labile toxin exhibits a 80% sequence homology with cholera toxin. 
      The presently available vaccine against cholera (Dukoral) contains inactivated 
      Vibrio cholerae bacteria and the recombinant non-toxic B subunit of cholera 
      toxin. Consequently, this vaccine displays also some efficacy against traveler's 
      diarrhoea with up to 25 % of travelers being protected against this disease. 
      Rotaviruses are the leading recognized cause of diarrhoea-related illness and 
      deaths among infants worldwide in developing and industrialized countries. Based 
      on the high incidence of this disease two oral vaccines have been developed and 
      are available in Europe in 2007. Due to the impact of rotavirus diseases also in 
      Austria vaccination against this disease has been already suggested in the 
      Austrian vaccination schedules for infants from 6-24 weeks of age. One of the two 
      vaccines, Rotarix, is an attenuated monovalent vaccine with a broad 
      cross-reactivity against the most frequent serotypes. The second one, RotaTeq, is 
      a pentavalent attenuated vaccine containing 5 human-bovine reassortants. Both 
      vaccines display 85-98% efficacy against severe rotavirus disease and an 
      excellent tolerability with no difference in side reactions to the placebo 
      controls, particularly with respect to intussusceptions.
FAU - Kollaritsch, Herwig
AU  - Kollaritsch H
AD  - Institut fur Spezifische Prophylaxe und Tropenmedizin, Zentrum fur Physiologie 
      und Pathophysiologie, Medizinische Universitat Wien, Kinderspitalgasse 15, 
      Vienna, Austria. Herwig.kollaritsch@meduniwien.ac.at
FAU - Wiedermann, Ursula
AU  - Wiedermann U
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Impfstoffe gegen Durchfallserkrankungen--am Beispiel der Impfstoffe gegen 
      Reisediarrhoe und gegen Rotavirus.
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - 0 (Bacterial Toxins)
RN  - 0 (Cholera Vaccines)
RN  - 0 (Enterotoxins)
RN  - 0 (Escherichia coli Proteins)
RN  - 0 (Escherichia coli Vaccines)
RN  - 0 (Rotavirus Vaccines)
RN  - 0 (heat stable toxin (E coli))
RN  - 9012-63-9 (Cholera Toxin)
RN  - D9K3SN2LNY (heat-labile enterotoxin, E coli)
SB  - IM
MH  - Bacterial Toxins/immunology
MH  - Cholera/immunology/prevention & control
MH  - Cholera Toxin/immunology
MH  - Cholera Vaccines/immunology/therapeutic use
MH  - Cross Reactions/immunology
MH  - Dysentery/epidemiology/microbiology/*prevention & control
MH  - Enterotoxins/immunology
MH  - Escherichia coli Infections/epidemiology/immunology/prevention & control
MH  - Escherichia coli Proteins/immunology
MH  - Escherichia coli Vaccines/immunology/therapeutic use
MH  - Humans
MH  - Rotavirus Infections/epidemiology/immunology/*prevention & control
MH  - Rotavirus Vaccines/immunology/*therapeutic use
MH  - *Travel
RF  - 32
EDAT- 2007/04/12 09:00
MHDA- 2007/08/10 09:00
CRDT- 2007/04/12 09:00
PHST- 2006/11/29 00:00 [received]
PHST- 2006/12/28 00:00 [accepted]
PHST- 2007/04/12 09:00 [pubmed]
PHST- 2007/08/10 09:00 [medline]
PHST- 2007/04/12 09:00 [entrez]
AID - 10.1007/s10354-007-0390-1 [doi]
PST - ppublish
SO  - Wien Med Wochenschr. 2007;157(5-6):102-6. doi: 10.1007/s10354-007-0390-1.